Intuitive Surgical stock falls over 5% as shares slide despite strong Q2 results and upbeat guidance

Traders Union
All News
Stocks
Intuitive surgical slides 5.22% today

Highlights

Intuitive Surgical reported Q2 2026 revenue up 19% to $2.89 billion and adjusted EPS of $2.80, surpassing consensus estimates.
Procedure volumes grew 16% with raised guidance, and the company plans a $500 million Malaysia facility and da Vinci 5 enhancements.
Shares of Intuitive Surgical trade between $367.87 to $384.54 with technicals showing near-term resilience but ongoing longer-term selling pressure.

Recurring revenue and guidance lift offset by lingering market skepticism

Intuitive Surgical reported fiscal Q2 2026 results with 19% revenue growth to $2.89 billion and adjusted EPS of $2.80, both ahead of consensus. The company recorded 16% quarterly growth in procedure volumes and raised its guidance for da Vinci procedure volumes for the full year. Approximately 85% of revenue was recurring, with new plans for a $500 million manufacturing facility in Penang, Malaysia, and ongoing advancements in the da Vinci 5 platform. Updates on My Intuitive+ renewals and broader software initiatives were also provided, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees a clear disconnect between Intuitive Surgical’s strong results and the negative price reaction. Despite robust revenue growth, solid recurring income, and new capacity expansions, medium- and long-term technical trends remain firmly bearish. He notes that recent technical structures do not support a sustainable bounce, with moving averages and weak ADX signaling low conviction upside. Kharitonov flags the intraday dominance of sellers as a sign investors remain cautious regardless of upbeat fundamentals. "Until the price reclaims the $390.05 level with increased momentum, I consider further upside limited and downside risks persistent."

Viktoras Karapetjanc, expert at Traders Union, believes Intuitive Surgical’s fundamentals remain strong following double-digit growth and rising guidance. Nearly all revenue is recurring, while investments in Malaysia and the da Vinci 5 platform reinforce long-term prospects. Karapetjanc points out that the current price dip offers fresh setups for buyers seeking exposure to a healthcare technology leader. "Despite short-term volatility, the bullish structure remains intact and I expect further growth as management delivers consistent innovation."

Parshwa Turakhiya, analyst, highlights that short-term momentum indicators are mixed but tilt slightly positive, with a bounce potential near $374.58 support. He sees overbought signals from the Stochastic RSI and Bull/Bear Power, suggesting careful entry is needed. Turakhiya notes sentiment is sensitive to intraday selling, despite a constructive oscillators’ setup. "I’m watching $377.38 for bullish confirmation, but would stay nimble as volatility levels remain elevated and sentiment can flip quickly."

Short-term resilience weakens as longer-term bearish signals dominate

ISRG is trading above its 20-day moving average (MA-20) at $374.58, but remains below both the 50-day (MA-50) at $390.05 and the 200-day (MA-200) at $474.77. This configuration signals short-term resilience, yet persistent medium- and long-term seller pressure, with a bearish trend confirmed by the MA-50 versus MA-200 alignment. Closest technical levels to monitor include resistance at $377.38 and support at $374.58. Momentum indicators reveal a mixed environment: the MACD is in buy territory, suggesting positive momentum, but the ADX registers 14.06, indicating a weak, trendless market. The RSI at 57.17 and CCI at 94.97 hint at constructive undertones, while the Stochastic RSI at 86.8 and Bull/Bear Power at 16.88 reflect overbought conditions and ongoing buyer dominance in the near term. The Awesome Oscillator does not provide directional confirmation. Intraday volatility is at 4.51%, and sellers have maintained control since the open as price nears the session low. Intraday momentum stands in contrast to the generally constructive signal from several oscillators.

Earlier, analysts noted that Intuitive Surgical's strong operational performance was tempered by ongoing technical weakness and rising competitive pressures. The current article adds that, despite continued mixed signals and short-term resilience, the prevailing scenario calls for close monitoring of breakout risk at $377.38 as a potential catalyst for further gains.

Source of Data: ISRG Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.